{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T09:42:05Z","timestamp":1792575725924,"version":"4.5.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"DOI":"10.1007\/s11523-026-01264-7","type":"journal-article","created":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T09:01:29Z","timestamp":1792573289000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Infliximab for Management of Immune-Related Adverse Events: A Retrospective Analysis"],"prefix":"10.1007","author":[{"given":"Filippos","family":"Koutroumpakis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Takigawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene Jeong-Ah","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anirudha","family":"Chatterjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidra","family":"Naz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilin","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Gouda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Philpott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5148-6130","authenticated-orcid":false,"given":"Yinghong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,21]]},"reference":[{"issue":"36","key":"1264_CR1","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021;39(36):4073\u2013126. https:\/\/doi.org\/10.1200\/JCO.21.01440.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1264_CR2","doi-asserted-by":"publisher","first-page":"230","DOI":"10.6004\/jnccn.2020.0012","volume":"18","author":"JA Thompson","year":"2020","unstructured":"Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, Bhatia S, et al. NCCN guidelines insights: management of immunotherapy-related toxicities, version 1.2020. J Natl Compr Canc Netw. 2020;18(3):230\u201341. https:\/\/doi.org\/10.6004\/jnccn.2020.0012.","journal-title":"J Natl Compr Canc Netw"},{"issue":"4","key":"1264_CR3","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1053\/j.gastro.2020.08.063","volume":"160","author":"M Dougan","year":"2021","unstructured":"Dougan M, Wang Y, Rubio-Tapia A, Lim JK. AGA clinical practice update on diagnosis and management of immune checkpoint inhibitor colitis and hepatitis: expert review. Gastroenterology. 2021;160(4):1384\u201393. https:\/\/doi.org\/10.1053\/j.gastro.2020.08.063.","journal-title":"Gastroenterology"},{"issue":"1","key":"1264_CR4","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/S1470-2045(23)00524-7","volume":"25","author":"Y Fujiwara","year":"2024","unstructured":"Fujiwara Y, Horita N, Adib E, Zhou S, Nassar AH, Asad ZUA, et al. Treatment-related adverse events, including fatal toxicities, in patients with solid tumours receiving neoadjuvant and adjuvant immune checkpoint blockade: a systematic review and meta-analysis of randomised controlled trials. Lancet Oncol. 2024;25(1):62\u201375. https:\/\/doi.org\/10.1016\/S1470-2045(23)00524-7.","journal-title":"Lancet Oncol"},{"issue":"6","key":"1264_CR5","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1038\/nri2340","volume":"8","author":"JH Cho","year":"2008","unstructured":"Cho JH. The genetics and immunopathogenesis of inflammatory bowel disease. Nat Rev Immunol. 2008;8(6):458\u201366. https:\/\/doi.org\/10.1038\/nri2340.","journal-title":"Nat Rev Immunol"},{"issue":"7152","key":"1264_CR6","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/nature06005","volume":"448","author":"RJ Xavier","year":"2007","unstructured":"Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007;448(7152):427\u201334. https:\/\/doi.org\/10.1038\/nature06005.","journal-title":"Nature"},{"issue":"3","key":"1264_CR7","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.cell.2020.06.001","volume":"182","author":"AM Luoma","year":"2020","unstructured":"Luoma AM, Suo S, Williams HL, Sharova T, Sullivan K, Manos M, et al. Molecular pathways of colon inflammation induced by cancer immunotherapy. Cell. 2020;182(3):655-71 e22. https:\/\/doi.org\/10.1016\/j.cell.2020.06.001.","journal-title":"Cell"},{"issue":"4","key":"1264_CR8","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.cgh.2022.10.004","volume":"21","author":"A Shirwaikar Thomas","year":"2023","unstructured":"Shirwaikar Thomas A, Hanauer S, Wang Y. Immune checkpoint inhibitor enterocolitis vs idiopathic inflammatory bowel disease. Clin Gastroenterol Hepatol. 2023;21(4):878\u201390. https:\/\/doi.org\/10.1016\/j.cgh.2022.10.004.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"1264_CR9","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.14309\/ajg.0000000000003465","volume":"120","author":"GR Lichtenstein","year":"2025","unstructured":"Lichtenstein GR, Loftus EV, Afzali A, Long MD, Barnes EL, Isaacs KL, et al. ACG clinical guideline: management of Crohn\u2019s disease in adults. Am J Gastroenterol. 2025;120(6):1225\u201364. https:\/\/doi.org\/10.14309\/ajg.0000000000003465.","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"1264_CR10","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1016\/j.gastro.2003.05.009","volume":"125","author":"CG Su","year":"2003","unstructured":"Su CG, Lichtenstein GR. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn\u2019s disease. Gastroenterology. 2003;125(5):1544\u20136. https:\/\/doi.org\/10.1016\/j.gastro.2003.05.009.","journal-title":"Gastroenterology"},{"key":"1264_CR11","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) criteria. Available from: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf."},{"issue":"1","key":"1264_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0577-1","volume":"7","author":"H Abu-Sbeih","year":"2019","unstructured":"Abu-Sbeih H, Ali FS, Wang X, Mallepally N, Chen E, Altan M, et al. Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor-induced colitis. J Immunother Cancer. 2019;7(1):93. https:\/\/doi.org\/10.1186\/s40425-019-0577-1.","journal-title":"J Immunother Cancer"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-026-01264-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-026-01264-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-026-01264-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T09:01:30Z","timestamp":1792573290000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-026-01264-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,21]]},"references-count":12,"alternative-id":["1264"],"URL":"https:\/\/doi.org\/10.1007\/s11523-026-01264-7","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,21]]},"assertion":[{"value":"9 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Yinghong Wang served as a consultant for Janssen, Ilyapharma, Sorriso, Abbvie, Ferring, and Therakos; participated on a science advisory board for Abbvie and Ferring; and received research funding from Janssen and 3D-matrix. Filippos Koutroumpakis, Yifan Xu, Kevin Shi, Kei Takigawa, Irene Jeong-Ah Lee, Anirudha Chatterjee, Sidra Naz, Yilin Song, Monica Desai, Mohamed Gouda, and Jessica Philpott declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board of The University of Texas MD Anderson Cancer Center (PA18-0472), which granted a waiver of informed consent due to the retrospective design and minimal risk to participants.","order":2,"name":"Ethics","label":"Ethical Approval and Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The datasets generated and analyzed during the current study are available from the corresponding author upon reasonable request.","order":3,"name":"Ethics","label":"Data Availability Statement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Y.W., who was the senior author of this article, developed the concept, was in charge of the overall direction and planning of the study, and contributed to the writing of the manuscript, with input from all authors. F.K. conducted the data collection, drafted the initial manuscript, and performed the biostatistical analysis. Y.X., K.S., K.T., I.J.L., A.C., and S.N. helped with data collection. All the authors critically revised the final version of the manuscript and have approved the final manuscript.","order":4,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}